Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy
- 24 June 2020
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (549)
- https://doi.org/10.1126/scitranslmed.aba2325
Abstract
Monoclonal antibodies that block the programmed cell death 1 (PD-1) checkpoint have revolutionized cancer immunotherapy. However, many major tumor types remain unresponsive to anti-PD-1 therapy, and even among responsive tumor types, most of the patients do not develop durable antitumor immunity. It has been shown that bispecific antibodies activate T cells by cross-linking the TCR/CD3 complex with a tumor-specific antigen (TSA). The class of TSAxCD3 bispecific antibodies have generated exciting results in early clinical trials. We have recently described another class of "costimulatory bispecifics" that cross-link a TSA to CD28 (TSAxCD28) and cooperate with TSAxCD3 bispecifics. Here, we demonstrate that these TSAxCD28 bispecifics (one specific for prostate cancer and the other for epithelial tumors) can also synergize with the broader anti-PD-1 approach and endow responsiveness-as well as long-term immune memory-against tumors that otherwise do not respond to antiPD-1 alone. Unlike CD28 superagonists, which broadly activate T cells and induce cytokine storm, TSAxCD28 bispecifics display little or no toxicity when used alone or in combination with a PD-1 blocker in genetically humanized immunocompetent mouse models or in primates and thus may provide a well-tolerated and "off the shelf" combination approach with PD-1 immunotherapy that can markedly enhance antitumor efficacy.This publication has 75 references indexed in Scilit:
- After TGN1412: Recent developments in cytokine release assaysJournal of Immunotoxicology, 2012
- Human thrombopoietin knockin mice efficiently support human hematopoiesis in vivoProceedings of the National Academy of Sciences of the United States of America, 2011
- Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T‐cellsBritish Journal of Pharmacology, 2010
- F0 generation mice fully derived from gene-targeted embryonic stem cells allowing immediate phenotypic analysesNature Biotechnology, 2006
- Comparative study of PSMA expression in the prostate of mouse, dog, monkey, and humanThe Prostate, 2006
- CD38 is expressed selectively during the activation of a subset of mature T cells with reduced proliferation but improved potential to produce cytokinesJournal of Leukocyte Biology, 2004
- High-throughput engineering of the mouse genome coupled with high-resolution expression analysisNature Biotechnology, 2003
- CD80 (B7-1) Binds Both CD28 and CTLA-4 with a Low Affinity and Very Fast KineticsThe Journal of Experimental Medicine, 1997
- Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity.The Journal of Experimental Medicine, 1994
- Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma CellsScience, 1993